Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Glycated Hemoglobin Testing Market by Product Type (Laboratory HbA1c Testing Products, Point of Care (POC) HbA1c Testing Products), by Technology (Chromatography, Immunoassay, Others) and by End User (Hospitals, Physical Examination Institution, Research Institutions, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03795

Pages: NA

Charts: NA

Tables: NA

Glycated hemoglobin is used to measure three-month average plasma glucose concentration. It is a standardized test that indicates the amount of HbA1c, a special form of glycated hemoglobin, in a persons blood during the past two to four months. A glycated hemoglobin test is used to diagnose type 2 diabetes by monitoring the amount of hemoglobin bound to the glucose.

The major factors that contribute to the growth of the glycated hemoglobin testing market include increasing diabetic patients, growing geriatric population, technological advancements in diagnosing diabetes, growth in the home healthcare market, and increased R&D activities in early diagnosis and efficient disease management. However, the availability of substitutes and high costs associated with glycated hemoglobin testing hinder the market growth. Increase in diabetic population and growing awareness about POC HbA1c testing in developing countries are expected to boost the market growth in the near future.

The glycated hemoglobin testing market is segmented on the basis of product, technology, end user, and region. On the basis of product type, the market is segmented into Laboratory HbA1c testing products and point of care (POC) HbA1c testing products. Based on technology, the market is segmented into chromatography, immunoassay, and others. On the basis of end user, the market is classified into hospitals, physical examination institution, research institutions, and others. By geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Alere Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Bayer AG, Randox Laboratories Ltd., Tosoh Corporation, ARKRAY, Inc., and A.Menarini Diagnostics Ltd.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market, which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

 Key Market Segments

  • By Product Type
    • Laboratory HbA1c Testing Products
    • Point of Care (POC) HbA1c Testing Products
  • By Technology
    • Chromatography
    • Immunoassay
    • Others
  • By End User
    • Hospitals
    • Physical Examination Institution
    • Research Institutions
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • ARKRAY, Inc.
  • Alere Inc.
  • Randox Laboratories Ltd.
  • Beckman Coulter, Inc.
  • Tosoh Corporation
  • A.Menarini Diagnostics Ltd.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: GLYCATED HEMOGLOBIN TESTING MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Laboratory HbA1c Testing Products

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Point Of Care (POC) HbA1c Testing Products

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: GLYCATED HEMOGLOBIN TESTING MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. Chromatography

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Immunoassay

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: GLYCATED HEMOGLOBIN TESTING MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Physical Examination Institution

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Research Institutions

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: GLYCATED HEMOGLOBIN TESTING MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Technology

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Glycated Hemoglobin Testing Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Technology
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Glycated Hemoglobin Testing Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Technology
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Glycated Hemoglobin Testing Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Technology
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Technology

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Glycated Hemoglobin Testing Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Technology
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Glycated Hemoglobin Testing Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Technology
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Glycated Hemoglobin Testing Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Technology
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Glycated Hemoglobin Testing Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Technology
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Glycated Hemoglobin Testing Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Technology
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Glycated Hemoglobin Testing Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Technology
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Glycated Hemoglobin Testing Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Technology
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Technology

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Glycated Hemoglobin Testing Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Technology
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Glycated Hemoglobin Testing Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Technology
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Glycated Hemoglobin Testing Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Technology
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Glycated Hemoglobin Testing Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Technology
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Glycated Hemoglobin Testing Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Technology
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Glycated Hemoglobin Testing Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Technology
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Glycated Hemoglobin Testing Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Technology
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Glycated Hemoglobin Testing Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Technology
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Glycated Hemoglobin Testing Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Technology
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Technology

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Glycated Hemoglobin Testing Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Technology
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Glycated Hemoglobin Testing Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Technology
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Glycated Hemoglobin Testing Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Technology
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Glycated Hemoglobin Testing Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Technology
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Glycated Hemoglobin Testing Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Technology
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Glycated Hemoglobin Testing Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Technology
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. F. Hoffmann-La Roche Ltd.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Alere Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bio-Rad Laboratories, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Beckman Coulter, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Bayer AG

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Randox Laboratories Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Tosoh Corporation

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. ARKRAY, Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. A.Menarini Diagnostics Ltd.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR LABORATORY HBA1C TESTING PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR POINT OF CARE (POC) HBA1C TESTING PRODUCTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR CHROMATOGRAPHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR IMMUNOASSAY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR PHYSICAL EXAMINATION INSTITUTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR RESEARCH INSTITUTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA GLYCATED HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. U.S. GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 20. U.S. GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CANADA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 22. CANADA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 23. CANADA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE GLYCATED HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ITALY GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ITALY GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 39. ITALY GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. UK GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 44. UK GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 45. UK GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. CHINA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 57. CHINA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. CHINA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. INDIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 63. INDIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 64. INDIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA GLYCATED HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. UAE GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 97. UAE GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 98. UAE GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA GLYCATED HEMOGLOBIN TESTING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA GLYCATED HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA GLYCATED HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 106. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 107. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 108. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 109. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 111. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 112. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 113. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ALERE INC.: KEY EXECUTIVES
  • TABLE 116. ALERE INC.: COMPANY SNAPSHOT
  • TABLE 117. ALERE INC.: OPERATING SEGMENTS
  • TABLE 118. ALERE INC.: PRODUCT PORTFOLIO
  • TABLE 119. ALERE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 121. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 122. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 123. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 124. BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. BECKMAN COULTER, INC.: KEY EXECUTIVES
  • TABLE 126. BECKMAN COULTER, INC.: COMPANY SNAPSHOT
  • TABLE 127. BECKMAN COULTER, INC.: OPERATING SEGMENTS
  • TABLE 128. BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
  • TABLE 129. BECKMAN COULTER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. BAYER AG: KEY EXECUTIVES
  • TABLE 131. BAYER AG: COMPANY SNAPSHOT
  • TABLE 132. BAYER AG: OPERATING SEGMENTS
  • TABLE 133. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 134. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. RANDOX LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 136. RANDOX LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 137. RANDOX LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 138. RANDOX LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 139. RANDOX LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. TOSOH CORPORATION: KEY EXECUTIVES
  • TABLE 141. TOSOH CORPORATION: COMPANY SNAPSHOT
  • TABLE 142. TOSOH CORPORATION: OPERATING SEGMENTS
  • TABLE 143. TOSOH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 144. TOSOH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. ARKRAY, INC.: KEY EXECUTIVES
  • TABLE 146. ARKRAY, INC.: COMPANY SNAPSHOT
  • TABLE 147. ARKRAY, INC.: OPERATING SEGMENTS
  • TABLE 148. ARKRAY, INC.: PRODUCT PORTFOLIO
  • TABLE 149. ARKRAY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. A.MENARINI DIAGNOSTICS LTD.: KEY EXECUTIVES
  • TABLE 151. A.MENARINI DIAGNOSTICS LTD.: COMPANY SNAPSHOT
  • TABLE 152. A.MENARINI DIAGNOSTICS LTD.: OPERATING SEGMENTS
  • TABLE 153. A.MENARINI DIAGNOSTICS LTD.: PRODUCT PORTFOLIO
  • TABLE 154. A.MENARINI DIAGNOSTICS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GLYCATED HEMOGLOBIN TESTING MARKET
  • FIGURE 3. SEGMENTATION GLYCATED HEMOGLOBIN TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GLYCATED HEMOGLOBIN TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGLYCATED HEMOGLOBIN TESTING MARKET
  • FIGURE 11. GLYCATED HEMOGLOBIN TESTING MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. GLYCATED HEMOGLOBIN TESTING MARKET FOR LABORATORY HBA1C TESTING PRODUCTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. GLYCATED HEMOGLOBIN TESTING MARKET FOR POINT OF CARE (POC) HBA1C TESTING PRODUCTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. GLYCATED HEMOGLOBIN TESTING MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 15. GLYCATED HEMOGLOBIN TESTING MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. GLYCATED HEMOGLOBIN TESTING MARKET FOR IMMUNOASSAY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. GLYCATED HEMOGLOBIN TESTING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. GLYCATED HEMOGLOBIN TESTING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 19. GLYCATED HEMOGLOBIN TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. GLYCATED HEMOGLOBIN TESTING MARKET FOR PHYSICAL EXAMINATION INSTITUTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. GLYCATED HEMOGLOBIN TESTING MARKET FOR RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. GLYCATED HEMOGLOBIN TESTING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: GLYCATED HEMOGLOBIN TESTING MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. ALERE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ALERE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ALERE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BIO-RAD LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. BECKMAN COULTER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. BECKMAN COULTER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. BECKMAN COULTER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. RANDOX LABORATORIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. RANDOX LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. RANDOX LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. TOSOH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. TOSOH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. TOSOH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. ARKRAY, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. ARKRAY, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. ARKRAY, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. A.MENARINI DIAGNOSTICS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. A.MENARINI DIAGNOSTICS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. A.MENARINI DIAGNOSTICS LTD.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Glycated Hemoglobin Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved